See the Whole Landscape Shape What's Next in Pharma
GBI Health unites global pharmaceutical data, AI capabilities and industry expertise to deliver future-ready solutions across the entire product lifecycle.
Products
GBI Health Data Intelligence Suite
Solutions
Full Life-Cycle Solutions for Pharmaceuticals
Powered by global drug pipeline data, the Competitive Landscape Analysis solution enables multidimensional analysis across drugs, targets, indications, and technologies. It helps R&D teams identify strategic opportunities, prioritize investments, and make more informed development decisions.
Drawing on data from six major global clinical trial registries, the Clinical R&D Insights solution provides deep visibility into global trial activity and protocol designs, helping teams optimize clinical development strategies and trial execution.
Drawing on data covering the National Reimbursement Drug List (NRDL), public procurement and tendering, Huiminbao (commercial health insurance), Patient Assistance Programs (PAPs), and healthcare policies and regulations, the Market Access Strategy solution supports market access planning, pricing analysis, and regional opportunity assessment to accelerate commercialization and market access.
Built on comprehensive researcher profiles, the GBI KOL/HCP Management solution enables researcher identification, segmentation, academic influence analysis, and collaboration network mapping, helping Medical Affairs, Marketing, and Sales teams improve researcher engagement and operational efficiency.
Industry News and Reports
Aggregating industry news and in-depth reports to help pharma companies stay ahead.
- Genentech acquires rights to Hanmi's novel obesity drug
On August 24, 2026, Hanmi Pharm announced that it has entered into an exclusive licensing agreement with Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY).
- Leads Bio submits NDA in China for opamtistomig in EP-NEC indication
On August 21, 2026, China-based Nanjing Leads Biolabs Co., Ltd. (9887.HK) announced that it has submitted a New Drug Application (NDA) to National Medical Products Administration (NMPA) for its investigational drug opamtistomig (LBL-024) as a monotherapy for advanced, previously treated extrapulmonary neuroendocrine carcinoma (EP-NEC).
- Yipinhong's gout drug APH03867 nodded for clinical trials by NMPA
On August 21, 2026, Yipinhong Pharmacy Co., Ltd. (Yipinhong, 300723.SZ) announced that its Category 1 chemical drug APH03867 Tablets has received clinical trial approval from China's National Medical Products Administration (NMPA) for the treatment of gout patients with hyperuricemia.
- ImmuneOnco's IMM0306 receives US IND approval for clinical trial in SLE
On August 21, 2026, ImmuneOnco Biopharmaceuticals (1541.HK) announced that its drug IMM0306 has received Investigational New Drug (IND) clearance from the U.S. FDA to conduct a Phase Ib/II clinical trial for the treatment of systemic lupus erythematosus (SLE).
- North China Pharma's hexavalent norovirus vaccine nodded for clinical trials by NMPA
On August 21, 2026, North China Pharmaceutical Co., Ltd. (600812.SH) announced that its hexavalent recombinant norovirus vaccine (Hansenula polymorpha) has received clinical trial approval from China's National Medical Products Administration (NMPA). Norovirus is the primary pathogen responsible for outbreaks of non-bacterial acute gastroenteritis.
- Simcere 2026 H1 financial report: innovative drug revenue Up 34.1%
On August 20, 2026, Simcere Pharmaceutical (2096.HK) released its interim financial results for the first half of 2026.
In-Depth, Exclusive Industry Reports
Curated by expert analysts, offering in-depth analysis of emerging industry trends and the competitive landscape.
Scan the QR code to follow the GBIHealth WeChat Official Account for industry news, live webinars, thematic reports, and more.
Reliable partner for 95%+ key global medical industry players
Our clients are drawn from across pharma, medical device firms, CROs/CDMOs, investors, consulting firms, and others
See the Whole Landscape Shape What's Next in Pharma
GBI Health unites global pharmaceutical data, AI capabilities and industry expertise to deliver future-ready solutions across the entire product lifecycle.
Contact Us